Abstract
Patients with end-stage renal disease die from cardiovascular disease at a much younger age than people in the general population do. Here, we review the evidence linking early renal insufficiency (ERI) to an increased cardiovascular risk. A number of cardiovascular risk factors become prevalent with ERI, including night-time hypertension, increase in serum levels of lipoprotein (a), homocysteine and asymmetric dimethyl-arginine, and insulin resistance. Also, an epidemiologic association between coronary artery disease (CAD) and nephrosclerosis, a frequent cause of ERI in the elderly, is documented. In the middle-aged, general population ERI, found in 8% of women and 9% of men, was not associated with cardiovascular disease. However, in a representative sample of middle-aged British men the risk of stroke was 60% higher for the subgroup of individuals with ERI. In people at high cardiovascular risk (mostly CAD), the Heart Outcomes Prevention Evaluation (HOPE) study found a 2-fold (unadjusted) or 1.4-fold (adjusted) higher incidence of cardiovascular outcomes with ERI. The incidence of primary outcome increased with the level of serum creatinine. At least four studies have determined the cardiovascular risk associated with ERI in hypertension. In Hypertension Detection and Follow-up Program, as in HOPE, cardiovascular mortality increased with higher serum creatinine levels (5-fold difference in cardiovascular mortality between the lowest and the highest creatinine strata). In patients with hypertension with low risk, the Hypertension Optimal Treatment and a small Italian trial found about a doubling in cardiovascular outcomes in ERI. However, in the Multiple Risk Factor Intervention Trial, not baseline serum creatinine level, but its increase on follow-up predicted future cardiovascular disease. These observational data suggest that ERI, independent of etiology, is a strong predictor of cardiovascular disease, present in 10% of a population at low, and up to 30% at high, cardiovascular risk. No prospective therapeutic trials aimed at reducing the cardiovascular burden in individuals with ERI are available. Subgroup analyses of the HOPE study indicate that ACE inhibition with ramipril is beneficial without an increased risk of adverse effects like acute renal failure or hyperkalemia. Thus the frequent practice of withholding ACE inhibitors from patients with mild renal insufficiency is unwarranted, especially since this identifies a group at high risk who appears to benefit most from treatment. In addition, there is evidence that ACE inhibitors improve renal outcomes in renal insufficiency. Prospective studies should test the predictive power of ERI for cardiovascular disease and therapeutic options.
Similar content being viewed by others
References
Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 1999; 10: 1053–8
Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147–52
Raine AEG, Schwarz U, Ritz E. The patient with uremia: hypertension and cardiac problems. In: Davison AM, et al. editors. Oxford textbook of clinical nephrology. Oxford: Oxford University Press, 1998: 1885–919
Besarab A, Bolton WK, Browne JK. The effects of normal as compared to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and erythropoietin. N Engl J Med 1998; 339: 584–90
Stefanski M, Schmidt KG, Waldherr R, et al. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996; 50: 1321–6
Kronenberg F, Kuen E, Ritz E, et al. Lp (a) concentrations in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105–15
Jungers P, Joly D, Massy Z, et al. Sustained reduction of hyperhomoysteinemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14: 2903–6
Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulnemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343–7
Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153–9
Tracy RE, Malcolm GT, Oalmann MC, et al. Nephrosclerosis in coronary artery disease. Mod Pathol 1994; 7: 301–9
McCullough PA, Soman SS, Sha SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000; 36: 679–84
Culleton BF, Larson MG, Wilson PWF, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–9
Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker of increased risk for stroke. Stroke 1997; 28: 557–63
Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36
Gerstein HC, Mann JFE, Qilong Y, et al. Albuminuria and cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421–6
Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and the effect of treatment of hypertension on renal function: HDFP results. Hypertension 1989; 13 Suppl. 1: I–80–I–93
Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–25
Schillaci G, Reboldi G, VerdecchiaP. High normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 688–94
Flack JM, Neaton JD, Daniels B, et al. Ethnicity and renal disease: lessons from the MRFIT trial and the treatment of mild hypertension study. Am J Kidney Dis 1993; 21 Suppl. 1: 31–40
Maschio G, Alberti D, Janin G, et al. Effects of the ACE inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45
Ruggenenti P, Perna P, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252–6
Bakris GL, Weir MR. Angiotensin converting enzyme inhibitor-associated elevations in serum-creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–93
The HOPE study investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53
The HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Lancet 2000; 255: 253–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mann, J.F.E., Gerstein, H.C., Pogue, J. et al. Cardiovascular Risk in Patients with Early Renal Insufficiency. Am J Cardiovasc Drugs 2, 157–162 (2002). https://doi.org/10.2165/00129784-200202030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129784-200202030-00003